Odyssey Health, Inc. (ODYY): debt financing — Odyssey Health extends convertible note maturities to March 31, 2023; adds $50K principal to one note

On December 30, 2022, the Company entered into five Promissory Note Amendments (the "Amendments"), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to March 31, 2023.

On December 30, 2022, the Company entered into a Promissory Note Amendment (the "Investor Amendment"), to the Promissory Notes entered into September 21, 2022, with Jonathan Lutz, an accredited investor. Pursuant to the Investor Amendment, the parties have agreed to extend the maturity date of the note to January 31, 2023.

On December 29, 2022, Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (the "Company"), entered into Amendment No. 4 to the Convertible Promissory Note (the "Amendment") to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC ("LGH"). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to March 31, 2023. As consideration, the Company shall paydown thirty-five thousand ($35,000) towards the principal amount outstanding and fifty thousand ($50,000) shall be added to the principal amount outstanding.

On December 30, 2022, the Company entered into a Promissory Note Amendment (the “Investor Amendment”), to the Promissory Notes entered into September 21, 2022, with Jonathan Lutz, an accredited investor.

On December 29, 2022, Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (the “Company”), entered into Amendment No. 4 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”).